Takeda gets quick appeal in US Actos antitrust case
MLex Summary: Takeda Pharmaceutical was granted leave to immediately appeal orders certifying classes of direct purchasers and end-payors in a US antitrust case over its diabetes drug Actos. See attached file. ...To view the full article, register now.
Already a subscriber? Click here to view full article